Eli Lilly and Co (LLY)
745.24
+13.91
(+1.90%)
USD |
NYSE |
Apr 23, 14:58
Eli Lilly Enterprise Value: 717.71B for April 22, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| April 22, 2024 | 717.71B |
| April 19, 2024 | 712.94B |
| April 18, 2024 | 731.61B |
| April 17, 2024 | 736.20B |
| April 16, 2024 | 732.36B |
| April 15, 2024 | 736.20B |
| April 12, 2024 | 737.02B |
| April 11, 2024 | 744.58B |
| April 10, 2024 | 746.85B |
| April 09, 2024 | 742.35B |
| April 08, 2024 | 761.41B |
| April 05, 2024 | 767.99B |
| April 04, 2024 | 752.65B |
| April 03, 2024 | 760.17B |
| April 02, 2024 | 748.74B |
| April 01, 2024 | 745.49B |
| March 28, 2024 | 762.05B |
| March 27, 2024 | 762.26B |
| March 26, 2024 | 759.14B |
| March 25, 2024 | 757.46B |
| March 22, 2024 | 755.06B |
| March 21, 2024 | 754.73B |
| March 20, 2024 | 757.20B |
| March 19, 2024 | 757.12B |
| March 18, 2024 | 747.50B |
| Date | Value |
|---|---|
| March 15, 2024 | 739.43B |
| March 14, 2024 | 745.67B |
| March 13, 2024 | 742.92B |
| March 12, 2024 | 740.17B |
| March 11, 2024 | 720.60B |
| March 08, 2024 | 747.01B |
| March 07, 2024 | 764.14B |
| March 06, 2024 | 763.77B |
| March 05, 2024 | 761.70B |
| March 04, 2024 | 775.66B |
| March 01, 2024 | 766.00B |
| February 29, 2024 | 738.96B |
| February 28, 2024 | 742.73B |
| February 27, 2024 | 749.27B |
| February 26, 2024 | 755.84B |
| February 23, 2024 | 753.58B |
| February 22, 2024 | 753.67B |
| February 21, 2024 | 731.13B |
| February 20, 2024 | 740.39B |
| February 16, 2024 | 765.48B |
| February 15, 2024 | 741.81B |
| February 14, 2024 | 741.36B |
| February 13, 2024 | 727.75B |
| February 12, 2024 | 722.33B |
| February 09, 2024 | 725.08B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
116.30B
Minimum
Oct 10 2019
775.66B
Maximum
Mar 04 2024
289.84B
Average
247.17B
Median
Dec 08 2021
Enterprise Value Benchmarks
| Amgen Inc | 199.39B |
| Biogen Inc | 34.12B |
| Madrigal Pharmaceuticals Inc | 3.733B |
| Vertex Pharmaceuticals Inc | 92.07B |
| Viking Therapeutics Inc | 6.059B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 2.190B |
| Revenue (Quarterly) | 9.353B |
| Total Expenses (Quarterly) | 5.813B |
| EPS Diluted (Quarterly) | 2.306 |
| Gross Profit Margin (Quarterly) | 80.88% |
| Profit Margin (Quarterly) | 23.41% |
| Earnings Yield | 0.76% |
| Operating Earnings Yield | 1.64% |
| Normalized Earnings Yield | 1.230 |